317 related articles for article (PubMed ID: 34139575)
1. Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT.
Bottoni G; Piccardo A; Fiz F; Siri G; Matteucci F; Rocca A; Nanni O; Monti M; Brain E; Alberini JL; Dib B; Sacchetti GM; Saggia C; Rossi V; Harbeck N; Wuerstlein R; Degenhardt T; DeCensi A; Rollandi GA; Gennari A
Eur J Radiol; 2021 Aug; 141():109821. PubMed ID: 34139575
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT.
Piccardo A; Puntoni M; Morbelli S; Massollo M; Bongioanni F; Paparo F; Altrinetti V; Gonella R; Gennari A; Iacozzi M; Sambuceti G; DeCensi A
Nuklearmedizin; 2015; 54(4):163-72. PubMed ID: 26165806
[TBL] [Abstract][Full Text] [Related]
3.
Liu C; Ma G; Zhang J; Cheng J; Yang Z; Song S
Ann Nucl Med; 2023 Dec; 37(12):675-684. PubMed ID: 37787851
[TBL] [Abstract][Full Text] [Related]
4. Head-to-Head Evaluation of
Ulaner GA; Jhaveri K; Chandarlapaty S; Hatzoglou V; Riedl CC; Lewis JS; Mauguen A
J Nucl Med; 2021 Mar; 62(3):326-331. PubMed ID: 32680923
[TBL] [Abstract][Full Text] [Related]
5. Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition.
Boers J; Venema CM; de Vries EFJ; Glaudemans AWJM; Kwee TC; Schuuring E; Martens JWM; Elias SG; Hospers GAP; Schröder CP
Eur J Cancer; 2020 Feb; 126():11-20. PubMed ID: 31891878
[TBL] [Abstract][Full Text] [Related]
6.
Liu C; Gong C; Liu S; Zhang Y; Zhang Y; Xu X; Yuan H; Wang B; Yang Z
Oncologist; 2019 Dec; 24(12):e1277-e1285. PubMed ID: 31337657
[TBL] [Abstract][Full Text] [Related]
7. 18F-FES PET/CT Improves the Detection of Intraorbital Metastases in Estrogen-Receptor-Positive Breast Cancer: Two Representative Cases and Review of the Literature.
Bodapati S; Abraham P; Chen A; Guilbault D; McDonald M; Matro J; Shatsky R; Obrzut S
Tomography; 2022 Apr; 8(2):1060-1065. PubMed ID: 35448720
[TBL] [Abstract][Full Text] [Related]
8. Does Measurement of First-Order and Heterogeneity Parameters Improve Response Assessment of Bone Metastases in Breast Cancer Compared to SUV
Azad GK; Cousin F; Siddique M; Taylor B; Goh V; Cook GJR
Mol Imaging Biol; 2019 Aug; 21(4):781-789. PubMed ID: 30250989
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic effectiveness of [
Bottoni G; Fiz F; Puntoni M; Matteucci F; Monti M; DeCensi A; Nanni O; Brain E; Alberini JL; Dib B; Sacchetti G; Trimboli P; Treglia G; Harbeck N; Sola S; Gennari A; Piccardo A
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2477-2485. PubMed ID: 36879065
[TBL] [Abstract][Full Text] [Related]
10. Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.
Kurland BF; Peterson LM; Lee JH; Schubert EK; Currin ER; Link JM; Krohn KA; Mankoff DA; Linden HM
Clin Cancer Res; 2017 Jan; 23(2):407-415. PubMed ID: 27342400
[TBL] [Abstract][Full Text] [Related]
11. [18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant.
Iqbal R; Yaqub M; Bektas HO; Oprea-Lager DE; de Vries EGE; Glaudemans AWJM; Aftimos P; Gebhart G; Beelen AP; Schuit RC; Windhorst AD; Boellaard R; Menke-van der Houven van Oordt CW
Clin Cancer Res; 2023 Jun; 29(11):2075-2084. PubMed ID: 36735488
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of tumour heterogeneity by
Liu C; Hu S; Xu X; Zhang Y; Wang B; Song S; Yang Z
Breast Cancer Res; 2022 Aug; 24(1):57. PubMed ID: 36028895
[TBL] [Abstract][Full Text] [Related]
13. Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with
Gennari A; Brain E; De Censi A; Nanni O; Wuerstlein R; Frassoldati A; Cortes J; Rossi V; Palleschi M; Alberini JL; Matteucci F; Piccardo A; Sacchetti G; Ilhan H; D'Avanzo F; Ruffilli B; Nardin S; Monti M; Puntoni M; Fontana V; Boni L; Harbeck N;
Ann Oncol; 2024 Jun; 35(6):549-558. PubMed ID: 38423389
[TBL] [Abstract][Full Text] [Related]
14. Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis.
Son SH; Lee SW; Jeong SY; Song BI; Chae YS; Ahn BC; Lee J
AJR Am J Roentgenol; 2015 Oct; 205(4):878-85. PubMed ID: 26204115
[TBL] [Abstract][Full Text] [Related]
15. The Predictive Value of Early Changes in
He M; Liu C; Shi Q; Sun Y; Zhang Y; Xu X; Yuan H; Zhang Y; Liu Y; Liu G; Di G; Yang Z; Wang Z; Shao Z
Oncologist; 2020 Nov; 25(11):927-936. PubMed ID: 32272493
[TBL] [Abstract][Full Text] [Related]
16. 18F-Fluoroestradiol PET/CT Correctly Diagnosed 18F-FDG-Avid Inflammatory Lymph Nodes in a Patient With Estrogen Receptor-Positive Breast Cancer.
Yamane T; Ueda S; Seto A; Kuji I
Clin Nucl Med; 2018 May; 43(5):379-380. PubMed ID: 29485433
[TBL] [Abstract][Full Text] [Related]
17. The Assessment of Estrogen Receptor Status and Its Intratumoral Heterogeneity in Patients With Breast Cancer by Using 18F-Fluoroestradiol PET/CT.
Yang Z; Sun Y; Xu X; Zhang Y; Zhang J; Xue J; Wang M; Yuan H; Hu S; Shi W; Zhu B; Zhang Y
Clin Nucl Med; 2017 Jun; 42(6):421-427. PubMed ID: 28221191
[TBL] [Abstract][Full Text] [Related]
18. Clinical and economic outcomes of adding [18F]FES PET/CT in estrogen receptor status identification in metastatic and recurrent breast cancer in the US.
Munter-Young R; Fuentes-Alburo A; DiGregorio N; Neeser K; Gultyaev D
PLoS One; 2024; 19(5):e0302486. PubMed ID: 38743917
[TBL] [Abstract][Full Text] [Related]
19. Women's Health Update: Growing Role of PET for Patients with Breast Cancer.
Ulaner GA; Vaz SC
Semin Nucl Med; 2024 Mar; 54(2):247-255. PubMed ID: 38365547
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Prognostic Value of
Albano D; Familiari D; Fornito MC; Scalisi S; Laudicella R; Galia M; Grassedonio E; Ruggeri A; Ganduscio G; Messina M; Spada M; Midiri M; Alongi P
Curr Radiopharm; 2020; 13(1):42-47. PubMed ID: 31595860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]